POSITIVE TOPLINE DATA ANNOUNCED

A Phase 3 Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC

A Phase 1/2 trial in combination with Bristol-Myers Squibb’s anti-PD-1 therapy, Opdivo® (nivolumab) in RCC

37th Annual J.P. Morgan Healthcare Conference
February 16, 2019, 10:00 a.m.-11:30 a.m. PT

30th Annual Piper Jaffray Healthcare Conference
Wednesday, November 28, 2018 at 2:30 p.m. Eastern Time.

AVEO TIVO-3 Topline Data Conference Call
Monday, November 5, 2018 at 5:00 p.m. Eastern Time

AVEO Oncology to Present at the 37th Annual J.P. Morgan Healthcare Conference
January 2, 2019

AVEO Oncology to Present TIVO-3 Data at the 2019 ASCO Genitourinary Cancers Symposium
January 2, 2019

AVEO Oncology Announces Immuno-Oncology Clinical Collaboration with AstraZeneca
December 12, 2018